SMC endorses five new therapies for NHS Scotland
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
Read Moreby Selina McKee | Apr 10, 2018 | News | 0
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
Read Moreby Selina McKee | Oct 10, 2017 | News | 0
Patients in Scotland with multiple myeloma and those with some types of hepatitis C have won NHS access to new treatment options after the Scottish Medicines Consortium backed routine use of Janssen’s Darzalex and Gilead’s Epclusa.
Read Moreby Selina McKee | Jan 26, 2017 | News | 0
The National Institute for Health and Care Excellence has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the NHS in England and Wales.
Read Moreby Selina McKee | Nov 7, 2016 | News | 0
The Scottish Medicines Consortium has endorsed the use of five new therapies by NHS Scotland to treat melanoma, ovarian cancer, hepatitis C, Fabry disease and bacterial vaginosis.
Read Moreby Selina McKee | Sep 26, 2016 | News | 0
The National Institute for Health and Care Excellence is endorsing Gilead’s pan-genotypic hepatitis C drug Epclusa for routine NHS use in England and Wales.
Read Moreby Selina McKee | Jul 20, 2016 | News | 0
Gilead’s Sovaldi-based combination therapy for hepatitis C has been cleared for use by European regulators to treat all six types of the virus, potentially eliminating the need for genotype testing.
Read Moreby Selina McKee | Jun 29, 2016 | News | 0
Gilead’s Sovaldi-based combination therapy for hepatitis C has been cleared for use by the US Food and Drug Administration to treat all six types of the virus, potentially eliminating the need for genotype testing.
Read Moreby Selina McKee | May 31, 2016 | News | 0
Six medicines, including two new combination therapies for chronic hepatitis C, are lining up for EU approval after having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
